Informations for shareholders

The company is operating under the name Bioceltix (registered EU trademark). The company is operating in the form of a joint-stock company.

The company is located at Bierutowska 57-59 Str., 51-317 Wrocław, Poland.

The company is registered in the Register of Entrepreneurs of the National Court Register under KRS number 0000744521, District Court for Wrocław-Fabryczna in Wroclaw, VI Commercial Division of the National Court Register.

The statutory capital of the company amounts to PLN 342.732,50, paid in statutory capital amounts to PLN 342.732,50.

Tax identification number (NIP): PL899-27-94-360.

Statistical number (REGON): 364963245.

The quantity of all shares totals to 3.427.325, including series A shares in the amount of 1.981.500, series B shares in the amount of 104.290, series C shares in the amount of 172.000, series D shares in the amount of 186.224, series E shares in the amount of 271.550, series F shares in the amount of 211.225, series G shares in the amount of 360.000 and series I shares in the amount of 140.536. The company’s shares are not privileged.

Shareholders structure:

Management Board of Bioceltix S.A. with its registered office in Wrocław, court registry no. 0000744521 (hereinafter the “Company”) notifies the Shareholders that it convenes an Ordinary General Meeting on June 24^th, 2021 at 11:00.

The Ordinary General Meeting will be held at the Notary’s Office Warczak-Mańdziak & Janicka at ul. Gwiaździsta 64 / lok. 28/1 (28^th floor) in Wrocław, with the following agenda:

1. Opening of the Meeting;
2. Election of the Chairman of the Meeting;
3. Confirmation that the Ordinary General Meeting has been properly convened and is capable to adopt resolutions;
4. Getting acquainted with the report of the Supervisory Board of the Company on the assessment of the financial statements, the report on the activities and the Management Board’s proposal to cover the loss for the financial year 2020.
5. Consideration of the Company’s financial statements for the financial year 2020.
6. Adoption of a resolution on the approval of the Company’s financial statements for the financial year 2020.
7. Consideration of the report on the activities of the Company for the financial year 2020.
8. Adoption of a resolution on the approval of the report on the Company’s activities for the financial year 2020.
9. Adoption of a resolution on the coverage of the loss for the financial year 2020.
10. Adoption of resolutions on granting a vote of approval to members of the governing bodies for the performance of their duties in year 2020.
11. Closing the Meeting.

The Management Board of Bioceltix JSC informs, that on April 23rd, 2021 the information was received about the registration on April 23rd, 2021 in the National Court Register by the District Court for Wrocław-Fabryczna in Wrocław, VI Commercial Department of the National Court Register, of increase in the statutory capital of Bioceltix JSC from PLN 292.678,90 to PLN 328.678,90 in connection with the issue of series G shares within the authorized capital.

The Management Board of Bioceltix JSC informs, that on January 26th, 2021 the information was received about the registration on January 25th, 2021 in the National Court Register by the District Court for Wrocław-Fabryczna in Wrocław, VI Commercial Department of the National Court Register, of increase in the statutory capital of Bioceltix JSC from PLN 271.556,40 to PLN 292.678,90 in connection with the issue of series F shares within the authorized capital.

Management Board of Bioceltix S.A. with its registered office in Wrocław (hereinafter the “Company”) notifies the Shareholders that it convenes an Extraordinary General Meeting on January 21, 2021 at 10:00.

The Management Board of Bioceltix JSC informs, that on November 30th, 2020 the information was received about the registration on November 25th, 2020 in the National Court Register by the District Court for Wrocław-Fabryczna in Wrocław, VI Commercial Department of the National Court Register, of increase in the statutory capital of Bioceltix S.A. from PLN 244.401,40 to PLN 271.556,40 in connection with the issue of series E shares within the authorized capital.

CALL TO DEPOSIT SHARES TO THE COMPANY Due to the entry into force of the Act of August 30, 2019 amending the Commercial Companies Code and certain other acts (Journal of Laws of 2019, item 1798), hereinafter referred to as the “Act”,

On July 8, 2020, the Management Board of Bioceltix JSC with its seat in Wrocław, KRS: 0000744521 (hereinafter the “Company”) notifies the Shareholders that it convenes the Ordinary General Meeting on July 30, 2020 at 10:00.

The Management Board of Bioceltix JSC informs, that on June 9th, 2020 the information was received about the registration on June 2nd, 2020 in the National Court Register by the District Court for Wrocław-Fabryczna in Wrocław,

The Management Board of Bioceltix JSC informs, that on March 3, 2020 the information was received about the registration on February 27, 2020 in the National Court Register by the District Court for Wrocław-Fabryczna in Wrocław,